Trial Profile
A phase II clinical study of F-1614 in patients with pheochromocytoma (including paraganglioma)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors FUJIFILM RI Pharma; FUJIFILM Toyama Chemical
- 01 Mar 2022 Primary endpoint (Biochemical response rate) has been met according to the results published in the Annals of Nuclear Medicine
- 01 Mar 2022 Status changed from recruiting to completed.
- 01 Mar 2022 Results assessing the efficacy and safety of single-dose [131I]meta-iodobenzylguanidine (131I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL) published in the Annals of Nuclear Medicine